MAP plus maintenance pegylated interferon α-2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA10504-LBA10504
Author(s):  
Stefan S. Bielack ◽  
Sigbjorn Smeland ◽  
Jeremy Whelan ◽  
Neyssa Marina ◽  
Jane Hook ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Pegylated Interferon ◽  
Interferon Α ◽  
High Grade ◽  
Histologic Response ◽  
Daily News ◽  
Online Supplement ◽  
First Results ◽  
High Grade Osteosarcoma ◽  
Final Text

LBA10504 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA2000-LBA2000
Author(s):  
Ulrich Herrlinger ◽  
Niklas Schaefer ◽  
Joachim Peter Steinbach ◽  
Astrid Weyerbrock ◽  
Peter Hau ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Newly Diagnosed ◽  
Daily News ◽  
Online Supplement ◽  
First Results ◽  
Final Text

LBA2000 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Saturday, June, 1, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 “good response” randomization.

2013 ◽  
Vol 31 (18_suppl) ◽  
pp. LBA10504-LBA10504 ◽  
Author(s):  
Stefan S. Bielack ◽  
Sigbjorn Smeland ◽  
Jeremy Whelan ◽  
Neyssa Marina ◽  
Jane Hook ◽  
...  
Keyword(s):  
Cox Model ◽  
Controlled Trial ◽  
Final Analysis ◽  
Pegylated Interferon ◽  
Interferon Α ◽  
High Grade ◽  
Treatment Optimization ◽  
Histologic Response ◽  
High Grade Osteosarcoma

LBA10504 Background: EURAMOS-1 (NCT00134030) is an international randomized controlled trial investigating treatment optimization in osteosarcoma on the basis of histologic response to preoperative chemotherapy (CT). In patients (pts) with “good response” (GR; <10% viable tumor at surgery) to induction CT, efficacy of maintenance therapy with pegylated interferon α-2b (Ifn) was investigated. Methods: Pts ≤40yrs with resectable localized or primary metastatic high-grade extremity or axial osteosarcoma were eligible for registration at diagnosis. Eligibility for randomization included: [a] receipt of two cycles pre-op methotrexate, doxorubicin, cisplatin (MAP); [b] complete macroscopic resection of primary tumor; and [c] no disease progression. GR pts were randomized (1:1) after surgery to four cycles MAP +/-Ifn. Ifn (0.5-1.0 μg/kg/wk) was given after CT until 2yr post registration. Primary endpoint: event free survival (EFS); secondary: overall survival, toxicity. The trial design sought improved 3yr EFS from 70% to 80% (80% power, 2-sided alpha 5%). The final analysis was planned after 147 EFS events. Results: 2,260 pts were registered (Apr 05 to Jun 11) from 17 countries (326 sites) making it the largest trial in this rare cancer. GR was reported in 1,034 pts and 715 consented to randomization (358 MAP, 357 MAPIfn) with baseline characteristics balanced by arm: median age 14yr, 59% male, 79% localized disease. 271/357 (76%) pts started Ifn; main reason for not starting was treatment refusal, 66/86. By Feb 13 234/271 had stopped Ifn. Median duration of Ifn if started was 455 days; grade 3+ toxicity during Ifn reported by 81pts (30%). Median follow-up is 3.1yr with 174 EFS events reported: 93 MAP, 81 MAPIfn. Hazard ratio for EFS from adjusted Cox model was 0.82 (95% CI 0.61-1.11; p=0.201) in favor of MAPIfn. Conclusions: With current follow-up, EFS for MAPIfn is not statistically superior to MAP alone in pts with high-grade osteosarcoma and good response to pre-op MAP. One-quarter of pts did not start Ifn, which may have influenced this finding. Further follow-up for events and survival continues. Clinical trial information: NCT00134030.

New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: A report from the Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and Radiation Epidemiology(WECARE) Study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. CRA9513-CRA9513
Author(s):  
Chaya S. Moskowitz ◽  
Joanne F. Chou ◽  
Suzanne L. Wolden ◽  
Jonine L. Bernstein ◽  
Jyoti Malhotra ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Childhood Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Childhood Cancer Survivors ◽  
Daily News ◽  
Online Supplement ◽  
Radiation Epidemiology ◽  
Childhood Cancer Survivor Study ◽  
Final Text

CRA9513 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)—PISCES study, NCT 01064310.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. CRA4502-CRA4502 ◽  
Author(s):  
Bernard J. Escudier ◽  
Camillo Porta ◽  
Petri Bono ◽  
Ugo De Giorgi ◽  
Omi Parikh ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Annual Meeting ◽  
Patient Preference ◽  
Renal Cell ◽  
Double Blind ◽  
Daily News ◽  
Double Blind Placebo ◽  
Online Supplement ◽  
Final Text

CRA4502 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. CRA3503-CRA3503 ◽  
Author(s):  
Dirk Arnold ◽  
Thierry Andre ◽  
Jaafar Bennouna ◽  
Javier Sastre ◽  
Pia J. Osterlund ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Phase Iii ◽  
Daily News ◽  
Online Supplement ◽  
Previously Treated ◽  
Final Text

CRA3503 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 3-3 ◽  
Author(s):  
Mathias J. Rummel ◽  
Norbert Niederle ◽  
Georg Maschmeyer ◽  
Andre G. Banat ◽  
Ulrich von Gruenhagen ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Line Treatment ◽  
First Line ◽  
Daily News ◽  
Online Supplement ◽  
Mantle Cell ◽  
Final Text ◽  
First Line Treatment

3 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA506-LBA506 ◽  
Author(s):  
Andre Robidoux ◽  
Gong Tang ◽  
Priya Rastogi ◽  
Charles E. Geyer ◽  
Catherine A. Azar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Operable Breast Cancer ◽  
Daily News ◽  
Online Supplement ◽  
B 41 ◽  
Final Text

LBA506 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA5002-LBA5002 ◽  
Author(s):  
Eric Pujade-Lauraine ◽  
Felix Hilpert ◽  
Béatrice Weber ◽  
Alexander Reuss ◽  
Andres Poveda ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Recurrent Ovarian Cancer ◽  
Phase Iii ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Final Text

LBA5002^ The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Correlation of molecular alterations with efficacy of everolimus in hormone-receptor–positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA509-LBA509
Author(s):  
Gabriel N. Hortobagyi ◽  
Martine J. Piccart-Gebhart ◽  
Hope S. Rugo ◽  
Howard A. Burris ◽  
Mario Campone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Hormone Receptor ◽  
Daily News ◽  
Online Supplement ◽  
Molecular Alterations ◽  
Hormone Receptor Positive ◽  
Final Text

LBA509 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus ipi alone in metastatic melanoma: E1608.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. CRA9007-CRA9007 ◽  
Author(s):  
F. Stephen Hodi ◽  
Sandra J. Lee ◽  
David F. McDermott ◽  
Uma N. M. Rao ◽  
Lisa H. Butterfield ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Daily News ◽  
Online Supplement ◽  
Gm Csf ◽  
Randomized Phase Ii ◽  
Final Text

CRA9007 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Saturday, June, 1, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Sign in / Sign up

Export Citation Format

Share Document